Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Efficacy of CD19-targeted Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) Therapy in Patients With Relapsed or Refractory B-cell Lymphoma

NCT05326243 is registered in ClinicalTrials.gov with Pell Bio-Med Technology Co., Ltd. as lead sponsor.

NCT NCT05326243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05326243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Efficacy of CD19-targeted Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) Therapy in Patients With Relapsed or Refractory B-cell Lymphoma
Lead sponsor
Pell Bio-Med Technology Co., Ltd.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 31, 2022
Completion date
March 31, 2027
Enrollment
49 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, follicular lymphoma grade 3a, follicular lymphoma grade 3b, large b-cell lymphoma, primary mediastinal large b cell lymphoma